Treating Type I Diabetes Using a Therapy That Targets C-peptide
Treating Type I Diabetes Using a Therapy That Targets C-peptide
Embedded Files
SLU ID 12-012 | GPR146 as a C-peptide receptor
SLU ID 12-012 | GPR146 as a C-peptide receptor
Intellectual Property Status
Intellectual Property Status
Seeking
Seeking
Patented
Know-how based
Licensee
Development partner
Commercial partner
Investment
University spin out
Background
Background
In diabetic models, C-peptide appears to counteract the deleterious effects of insulin in several tissues, including the kidneys and the vasculature. This suggests that C-peptide may represent a novel threapeutic for treating diabetes-assoicated diseases.
Overview
Overview
Researchers at Saint Louis University have demonstrated that the orphan G protein coupled receptor, GPR146, is a likely candidate for the C-peptide receptor. This potentially enables the design of C-peptide agonists and sensitizers.
Benefits
Benefits
The potential benefits of this technology include:
Increasing the potential treatments for diabetes-associated diseases and complications
Increasing the experimental models available for studying diabetes-associated complications
Applications
Applications
The potential applications of this technology include treating various diabetes-associated diseases such as:
peripheral vascular disease
diabetic nephropathy
Opportunity
Opportunity
Saint Louis University is seeking a partner to further develop and commercialize this technology.
Report abuse